NCT00117104View on ClinicalTrials.gov

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

PHASE4CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
End Stage Renal Disease
Interventions
DRUG

Aranesp®

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00117104 - Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis | Biotech Hunter | Biotech Hunter